Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

unknown133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_3

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

NCT04585490
recruitingphase_2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
unknown

Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer

NCT04000425

Clinical Trials (3)

Showing 3 of 3 trials
NCT04585490Phase 3

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
NCT04585477Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Recruiting
NCT04000425

Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3